| 1. |
- Moberg, Christina, et al.
(författare)
-
De unga gör helt rätt när de stämmer staten
- 2022
-
Ingår i: Aftonbladet. - 1103-9000.
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- 1 620 forskare och lärare i forskarvärlden: Vi ställer oss bakom Auroras klimatkrav
|
|
| 2. |
- Axelsson Fisk, Sten, et al.
(författare)
-
Chronic Obstructive Pulmonary Disease in Sweden: an intersectional multilevel analysis of individual heterogeneity and discriminatory accuracy
- 2018
-
Ingår i: SSM - Population Health. - : Elsevier BV. - 2352-8273. ; 4, s. 334-346
-
Tidskriftsartikel (refereegranskat)abstract
- Socioeconomic, ethnic and gender disparities in Chronic Obstructive Pulmonary Disease (COPD) risk are well established but no studies have applied multilevel analysis of individual heterogeneity and discriminatory accuracy (MAIHDA) within an intersectional framework to study this outcome. We study individuals at the first level of analysis and combinations of multiple social and demographic categorizations (i.e., intersectional strata) at the second level of analysis. Here we used MAIHDA to assess to what extent individual differences in the propensity of developing COPD are at the intersectional strata level. We also used MAIHDA to determine the degree of similarity in COPD incidence of individuals in the same intersectional stratum. This leads to an improved understanding of risk heterogeneity and of the social dynamics driving socioeconomic and demographic disparities in COPD incidence. Using data from 2,445,501 residents in Sweden aged 45–65, we constructed 96 intersectional strata combining categories of age, gender, income, education, civil- and migration status. The incidences of COPD ranged from 0.02% for young, native males with high income and high education who cohabited to 0.98% for older native females with low income and low education who lived alone. We calculated the intra-class correlation coefficient (ICC) that informs on the discriminatory accuracy of the categorizations. In a model that conflated additive and interaction effects, the ICC was good (20.0%). In contrast, in a model that measured only interaction effects, the ICC was poor (1.1%) suggesting that most of the observed differences in COPD incidence across strata are due to the main effects of the categories used to construct the intersectional matrix while only a minor share of the differences are attributable to intersectional interactions. We found conclusive interaction effects. The intersectional MAIHDA approach offers improved information to guide public health policies in COPD prevention, and such policies should adopt an intersectional perspective.
|
|
| 3. |
- Barot, Shabane, et al.
(författare)
-
Ras i genetikens tidevarv
- 2020
-
Ingår i: Fronesis. - Malmö, Sweden : Tidskriftföreningen Fronesis. - 1404-2614. ; :66-67, s. 8-17
-
Tidskriftsartikel (populärvet., debatt m.m.)
|
|
| 4. |
|
|
| 5. |
- Bjerkeli, Pernilla J., et al.
(författare)
-
Overuse of methylphenidate : an analysis of Swedish pharmacy dispensing data
- 2018
-
Ingår i: Clinical Epidemiology. - : Dove Press. - 1179-1349. ; 10, s. 1657-1665
-
Tidskriftsartikel (refereegranskat)abstract
- Purpose: To identify overuse of methylphenidate and to investigate patterns of overuse in relation to sociodemographic and clinical characteristics. Patients and methods: Swedish national, pharmacy dispensing data were analyzed for all 56,922 individuals aged 6-79 years, who filled a methylphenidate prescription between 2010 and 2011. Overuse was defined as having above 150% days covered by the dispensed amount during 365 days from the first prescription fill, assuming use at the maximum recommended daily dose. Results: In total, 4,304 individuals (7.6% of the methylphenidate users) were categorized as overusers. The risk of overuse increased with age (OR for 46-65 years vs 6-12 years 17.5, 95% CI 14.3-21.3), and was higher in men (OR 1.4, 95% CI 1.3-1.5) and individuals with low income (OR 1.1, 95% CI 1.0-1.2), as well as in individuals with an attention deficit hyperactivity disorder (ADHD) diagnosis (OR 1.4, 95% CI 1.3-1.6), health care visits (OR 1.3, 95% CI 1.2-1.4), previous ADHD medication use (OR 2.6, 95% CI 2.4-2.8), and previous diagnosis of mental and behavioral disorders due to psychoactive substance use (OR 2.1 95% CI 2.0-2.3). Conclusion: Among individuals using methylphenidate in Sweden, 7.6% receive amounts that are larger than what they should have a medical need for, assuming that they were using the maximum recommended daily dose 365 days per year. Notably, the prevalence of overuse was associated with previous diagnosis of alcohol and drug misuse. The prevalence was also positively associated with higher age and previous use of ADHD medication. These findings may point toward a link between exposure time and overuse. However, future studies with long-term data are needed to investigate this.
|
|
| 6. |
- Bjerkeli, Pernilla J., et al.
(författare)
-
Sociodemographic patterns in pharmacy dispensing of medications for erectile dysfunction in Sweden
- 2018
-
Ingår i: European Journal of Clinical Pharmacology. - : Springer. - 0031-6970 .- 1432-1041. ; 74:2, s. 209-218
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE: The purpose of this study is to investigate the relationship between sociodemographic factors and pharmacy dispensing of medications for erectile dysfunction (ED) in the general population of middle-aged and elderly men. By considering a number of medical conditions that could promote or contraindicate use of ED medication, the analysis could help capture prescription patterns that might not be explained by medical needs.METHODS: Individual-level pharmacy dispensing data from 2006 for a population-based cohort of 216,148 men aged 45-79 years in the county Scania, Sweden, were analysed. Multiple logistic regression was applied, and area under the receiver operating characteristic curve (AUC) was calculated to quantify the discriminatory accuracy (DA) of the associations. National trends in pharmacy dispensing of ED medication between 2006 and 2016 were also analysed.RESULTS: Pharmacy dispensing of ED medication increased between 2006 and 2016, particularly among men aged 65-79 years (from 6.8 to 9.2%). Dispensing of ED medication was positively associated with higher socioeconomic position, and divorced and widowed men were more likely to fill a prescription with ED medication than married men. These associations remained after adjusting for medical conditions. The DA of the associations was, however, rather low (AUC = 0.69 among 45-64 year olds and AUC = 0.65 among 65-79 year olds).CONCLUSIONS: Pharmacy dispensing of ED medication seem linked to the individuals socioeconomic position, age and marital status suggesting sociodemographic disparities in the pharmacy dispensing targeting sexual function. However, the low DA of the associations shows the limited capacity of these factors to predict ED medication use at the individual level.
|
|
| 7. |
- Bjerkeli, Pernilla J., et al.
(författare)
-
Testosterone prescribing in the population — a short social epidemiological analysis in Sweden
- 2016
-
Ingår i: Pharmacoepidemiology and Drug Safety. - : Wiley. - 1053-8569 .- 1099-1557. ; 25:1, s. 11-15
-
Tidskriftsartikel (refereegranskat)abstract
- PURPOSE: In recent years, there has been an increased interest for use of pharmaceutical testosterone among elderly men. However, it is still scarcely studied if this use is conditioned by socioeconomic factors in the general population of elderly men.METHODS: Using individual-level data from a population-based cohort of men aged 65-84 years in the County Scania, Sweden, we analysed testosterone use in 2006 in relation to demographic and socioeconomic factors by means of multiple logistic regression. We also analysed national data at the ecological level to investigate trends in prescribing between 2006 and 2014.RESULTS: The prevalence of testosterone use in Sweden among 65- to 84-year-old men increased by 83%, from 3.3 per 1000 men in 2006 to 6.0 in 2014. Testosterone use was more than twice as common in men in the highest income quintile compared with those in the lowest (0.68% versus 0.25%, odds ratio 2.69 and 95% confidence interval 1.80-4.02). Besides in the high-income group, testosterone use was highest in 65- to 69-year-old men, divorced men and, specially, in men with a previous hospital diagnose of hypogonadism.CONCLUSIONS: Our findings show socioeconomic inequities in prescription of testosterone. This is a short analysis based on limited data, but because information on this topic is scarce, our analysis adds a relevant piece of evidence and highlights the need for further research.
|
|
| 8. |
|
|
| 9. |
- Bredström, Anna, 1972-, et al.
(författare)
-
Conceptual unclarity about COVID-19 ethnic disparities in Sweden: Implications for public health policy
- 2023
-
Ingår i: Health. - : SAGE Publications. - 1363-4593 .- 1461-7196. ; 27:2, s. 186-200
-
Tidskriftsartikel (refereegranskat)abstract
- The COVID-19 pandemic has shed light on abundant racial and ethnic health disparities in many countries around the world. In Sweden, statistics on COVID-19 mortality and morbidity from both the first and the second wave of the pandemic show that foreign-born individuals have been disproportionately affected as compared to Swedish-born individuals. However, as demonstrated in this article, key stakeholders including politicians and public authorities, mainstream media, and medical researchers do not draw on the same explanatory framework when conceptualizing the health disparity. Probing the different discourses that were articulated through oral and written accounts during the first wave, the article identifies three different frameworks of how ethnic health disparities in relation to COVID-19 were understood in Sweden: the socioeconomic framework, the cultural framework and the biological framework. In a concluding discussion, we discuss the importance of our findings for health policy and argue for continued interrogation of epidemiological knowledge production from a critical vantage point in order to successfully combat health inequalities.
|
|
| 10. |
|
|
| 11. |
- Cohen, Deborah, et al.
(författare)
-
The whistleblowing drama behind Astellas’s suspension from the ABPI
- 2019
-
Ingår i: BMJ: British Medical Journal. - : BMJ. - 1756-1833. ; 366
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- The Japanese drug company Astellas has had its knuckles rapped for wrongdoing four times in less than three years. Now Deborah Cohen, Shai Mulinari, and Piotr Ozieranski reveal fresh claims about the treatment of an employee who offered to help it clean up its act
|
|
| 12. |
- Danielsson, Erna, 1954-, et al.
(författare)
-
Sociologiska perspektiv på coronakrisen : Fyra sociologer om samhällets reaktion på covid-19
- 2020
-
Ingår i: Sociologisk forskning. - Annelöv : Sveriges sociologförbund. - 0038-0342 .- 2002-066X. ; 57:1, s. 67-76
-
Tidskriftsartikel (övrigt vetenskapligt/konstnärligt)abstract
- Sociologisk Forskning bad fyra sociologer i Sverige att svara på några korta frågor om coronapandemin och vårt samhälles hantering av den.Deras tidigare forskning har på olika sätt berört olika frågor såsom socialmedicin och medicinsk kunskapsproduktion, sociala nätverks betydelse för smittspridning, samhällets hantering av kriser och risker, genusaspekter av samhällskriser samt dynamiken mellan expertis, politiker och medborgare i beslutsfattande och debatter kring frågor där expertkunskap är centralt. Utifrån svaren på frågorna redigerade tidskriftens redaktörer en sammanhängande text, som de fyra forskarna sedan kunde ändra och göra tillägg i. Resultatet är en gemensam text som påminner om ett samtal. Den slutliga texten färdigställdes den 8 april 2020 .De fyra medverkande forskarna är Erna Danielsson, docent i sociologi vid Mittuni-versitetet och föreståndare för Risk and Crisis Research Centre (RCR), som forskar om samhällets krishantering vid såväl vardagskriser som större händelser och specifikt genus och krishantering; Fredrik Liljeros, professor i sociologi vid Stockholms universitet, som genomförde sitt postdoktorprojekt på dåvarande Smittskyddsinstitutet tillsammans med nuvarande statsepidemiologen Anders Tegnell och i dag bedriver forskning om hur människors kontaktnätverk påverkar spridningsdynamik; Shai Mulinari, docent i sociologi vid Lunds universitet, som bedriver forskning om medicinsk kunskapsproduktion, läkemedelsindustrin, epidemiologi och folkhälsa; samt Linda Soneryd, professor i sociologi vid Göteborgs universitet, som forskat om miljörelaterade risker och kriser samt om hur demokrati och deltagande förstås i anslutning till expertfrågor.
|
|
| 13. |
|
|
| 14. |
- Fabbri, Alice, et al.
(författare)
-
Content and strength of conflict of interest policies at Scandinavian Medical Schools: a cross sectional study
- 2022
-
Ingår i: BMC Medical Education. - : Springer Science and Business Media LLC. - 1472-6920. ; 22
-
Tidskriftsartikel (refereegranskat)abstract
- BackgroundConcerns around staffs’ and students’ interactions with commercial entities, for example drug companies, have led several North American medical schools to implement conflict of interest (COI) policies. However, little is known about COI policies at European medical schools. We analysed the content and strength of COI policies at Scandinavian medical schools.MethodsWe searched the websites of medical schools in Denmark, Norway, and Sweden and emailed the Deans for additional information. Using comparable methodology to previous studies, the strength of the COI policies was rated on a scale from 0 to 2 across 11 items (higher score more restrictive); we also assessed the presence of oversight mechanisms and sanctions.ResultsWe identified 77 unique policies for 15 medical schools (range 2–8 per school). Most of the policies (n = 72; 94%) were University wide and only five (6%) were specific for the medical schools. For six of eleven items one or more schools had a restrictive policy (score of two). None of the schools had a restrictive policy for the five additional items (speaking relationships, sales representatives, on-site education activities, medical school curriculum, and drug samples). Honoraria was the item with the highest score, with eight of the 15 schools having a score of two. Thirteen of the 15 schools had policies that identified a party responsible for policy oversight and mentioned sanctions for non-compliance.ConclusionOur study provides the first evaluation of all Scandinavian medical schools’ COI policies. We found that the content of COI policies varies widely and still has shortcomings. We encourage Scandinavian medical schools to develop more stringent COI policies to regulate industry interactions with both faculty and students.
|
|
| 15. |
- Fabbri, Alice, et al.
(författare)
-
Sunshine Policies and Murky Shadows in Europe: Disclosure of Pharmaceutical Industry Payments to Health Professionals in Nine European Countries
- 2018
-
Ingår i: International Journal of Health Policy and Management. - : Maad Rayan Publishing Company. - 2322-5939. ; 7:6, s. 504-509
-
Tidskriftsartikel (refereegranskat)abstract
- Relationships between health professionals and pharmaceutical manufacturers can unduly influence clinical practice. These relationships are the focus of global transparency efforts, including in Europe. We conducted a descriptive content analysis of the transparency provisions implemented by February 2017 in nine European Union (EU) countries concerning payments to health professionals, with duplicate independent coding of all data. Using an author-generated, semi-structured questionnaire, we collected information from each disclosure policy/code on: target industries, categories of healthcare professionals covered, scope of payments included, location and searchability of the disclosed data. Our analysis shows that although important improvements have been put in place in the past few years, significant gaps remain in disclosure requirements and their implementation. The situation differs substantially from country to country and the most striking differences are between governmental and self-regulatory approaches, especially with regard to the comprehensiveness of the disclosed data. In many cases, individuals can still opt out and reporting is incomplete, with common influential gifts such as food and drink excluded. Finally, in several countries data are only available as separate PDFs from companies, thus making the payment reports difficult to access and analyse. In order to overcome these gaps, minimum standards for disclosures should be implemented across Europe. All payments to healthcare professionals and organizations should be included, all health-related industries should be required to submit reports, and usability of disclosed data should be guaranteed.
|
|
| 16. |
-
Genetik och ras
- 2020
-
Samlingsverk (redaktörskap) (övrigt vetenskapligt/konstnärligt)
|
|
| 17. |
- Hagen, Niclas, et al.
(författare)
-
Genetics and democracy-what is the issue?
- 2012
-
Ingår i: Journal of Community Genetics. - : Springer Science and Business Media LLC. - 1868-6001 .- 1868-310X.
-
Tidskriftsartikel (refereegranskat)abstract
- Current developments in genetics and genomics entail a number of changes and challenges for society as new knowledge and technology become common in the clinical setting and in society at large. The relationship between genetics and ethics has been much discussed during the last decade, while the relationship between genetics and the political arena-with terms such as rights, distribution, expertise, participation and democracy-has been less considered. The purpose of this article is to demonstrate the connection between genetics and democracy. In order to do this, we delineate a notion of democracy that incorporates process as well as substance values. On the basis of this notion of democracy and on claims of democratisation in the science and technology literature, we argue for the importance of considering genetic issues in a democratic manner. Having established this connection between genetics and democracy, we discuss this relation in three different contexts where the relationship between genetics and democracy becomes truly salient: the role of expertise, science and public participation, and individual responsibility and distributive justice. As developments within genetics and genomics advance with great speed, the importance and use of genetic knowledge within society can be expected to grow. However, this expanding societal importance of genetics might ultimately involve, interact with, or even confront important aspects within democratic rule and democratic decision-making. Moreover, we argue that the societal importance of genetic development makes it crucial to consider not only decision-making processes, but also the policy outcomes of these processes. This argument supports our process and substance notion of democracy, which implies that public participation, as a process value, must be complemented with a focus on the effects of policy decisions on democratic values such as distributive justice.
|
|
| 18. |
- Hakariya, Hayase, et al.
(författare)
-
Continued cancer drug approvals in Japan and Europe after market withdrawal in the United States : A comparative study of accelerated approvals
- 2024
-
Ingår i: Clinical and Translational Science. - 1752-8062. ; 17:7, s. 13879-13879
-
Tidskriftsartikel (refereegranskat)abstract
- Regulatory authorities must balance ensuring evidence of efficacy and safety of new drugs. Various regulatory pathways, such as the accelerated approval program in the United States (US), allow authorities to quickly approve drugs for severely ill patients by granting market authorization based on surrogate end points and pending confirmatory trials. In this cross-sectional study, we considered 23 indications of cancer drugs that received accelerated approval by the US Food and Drug Administration (FDA) but were subsequently withdrawn as of April 2023. Our investigation extended to assessing the regulatory status of these accelerated approvals in the European Union (EU) and Japan, examining relevant regulatory documents and identifying factors contributing to the withdrawal in the United States. Comparing regions, we found that for 52% (12/23) and 30% (7/23) of withdrawn accelerated approvals in the United States, sponsors had also sought marketing authorization from the European Medicines Agency (EMA) and Japan's Pharmaceuticals and Medical Devices Agency (PMDA), respectively. As of the April 30, 2023 study cutoff date, 83% (10/12) of drug-indication pairs remained approved by the EMA, while the PMDA retained 100% (7/7). For these indications, the time from FDA withdrawal until the study cutoff date ranged from 0.23 years to 11.45 years for EMA approvals (median: 1.28 years) and 1.10 years to 11.45 years for PMDA approvals (median: 3.22 years). These findings highlight substantial regulatory discrepancies concerning cancer drugs with unconfirmed benefits. Addressing these discrepancies may involve requiring pharmaceutical companies to confirm clinical benefits using more robust end points and fostering international harmonization in regulators' assessment.
|
|
| 19. |
- Holmberg, Tora, et al.
(författare)
-
Determining discourse on bio-objects
- 2012
-
Ingår i: International Innovation. - : Research Media Ltd. ; :September, s. 24-26
-
Tidskriftsartikel (populärvet., debatt m.m.)abstract
- Social and educational scientists Drs Tora Holmberg, Malin Ideland and Shai Mulinari discuss their progress so far on a research project addressing the contemporary and controversial subject of cybrids and the discourse around them
|
|
| 20. |
- Holmberg, Tora, 1967-, et al.
(författare)
-
Determining discourse on bio-objects
- 2012
-
Ingår i: International Innovation. ; :September, s. 24-26
-
Tidskriftsartikel (populärvet., debatt m.m.)
|
|
| 21. |
- Ivert, Anna-Karin, et al.
(författare)
-
Appropriate assessment of ethnic differences in adolescent use of psychotropic medication : multilevel analysis of discriminatory accuracy
- 2016
-
Ingår i: Ethnicity and Health. - : Informa UK Limited. - 1355-7858 .- 1465-3419. ; 21:6, s. 578-595
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: In the present study, we used a multilevel approach to investigate the role of maternal country of birth (MCOB) in predicting adolescent use of psychotropic medication in Sweden.Design: Using the Swedish Medical Birth Register we identified all 428,314 adolescents born between 1987 and 1990 and who were residing in Sweden in the year they turned 18. We applied multilevel logistic regression analysis with adolescents (level 1) nested within MCOBs (level 2). Measures of association (odds ratio) and measures of variance (intra-class correlation (ICC)) were calculated, as well as the discriminatory accuracy by calculating the area under the Receiver Operator Characteristic (AU-ROC) curve.Results: In comparison with adolescents with Swedish-born mothers, adolescents with mothers born in upper-middle, lower-middle and low-income countries were less likely to use psychotropic medication. However, the variance between MCOBs was small (ICC = 2.5 in the final model) relative to the variation within MCOBs. This was confirmed by an AU-ROC value of 0.598.Conclusions: Even though we found associations between MCOB and adolescent use of psychotropic medication, the small ICC and AU-ROC indicate that MCOB appears to be an inaccurate context for discriminating adolescent use of psychotropic medication in Sweden.
|
|
| 22. |
- Larkin, James, et al.
(författare)
-
Payments to healthcare organisations reported by the medical device industry in Europe from 2017 to 2019 : An observational study
- 2024
-
Ingår i: Health Policy and Technology. - 2211-8837. ; 13:2
-
Tidskriftsartikel (refereegranskat)abstract
- Objective: Medical device industry payments to healthcare organisations (HCOs) can create conflicts of interest which can undermine patient care. One way of addressing this concern is by enhancing transparency of industry financial support to HCOs. MedTech Europe, a medical device trade body, operate a system of disclosure of education payments to European HCOs. This study aimed to characterise payments reported in this database and to evaluate the disclosure system. Methods: An observational study of education-related payments to HCOs reported by the medical device industry in Europe was conducted. Data was manually extracted from transparentmedtech.eu. The primary outcome variable is the value of the payments, overall, and for each year, payment type, and country. The accessibility, availability and quality of the database was also analysed, using a proforma with 15 measures. Results: Overall, 116 medical device companies reported education-related payments in 53 European and non-European countries, valuing over €425 million between 2017 and 2019, increasing in value between 2017 and 2019, from €93,798,419 to €175,414,302. Ten countries accounted for 94% of all payments and ten companies accounted for 80% of all payments. The accessibility, availability and quality of the database rated low for six measures, medium for six measures, and high for three measures. Conclusion: There is a large amount of education-related payments from medical device companies to European HCOs, creating substantial potential for conflicts of interest. MedTech Europe's disclosure system has many shortcomings. A European-wide publicly mandated disclosure system for both the medical device and pharmaceutical industries should be introduced. Public interest summary: The medical device industry pay healthcare organisations (e.g. hospitals) large amounts of money. Industry states that this money is to help pay for healthcare professionals’ education. However, these payments can have a negative impact on healthcare professionals’ decision-making. This study sought to examine a website run by MedTech Europe, a representative body for the medical device industry, which outlines details of some of these payments (www.transparentmedtech.eu). Our analysis found that between 2017 and 2019 the medical device industry made ‘education’ payments valuing €425 million to healthcare organisations in Europe. We also assessed how comprehensive and user-friendly the database was and found a range of issues. For example, the database is not downloadable and some other important types of payments, such as payments for consultancy, are not included. We concluded that a mandatory database for both the medical device and pharmaceutical industry run by the European Union, would significantly improve transparency.
|
|
| 23. |
|
|
| 24. |
- Merlo, Juan, et al.
(författare)
-
The tyranny of the averages and the indiscriminate use of risk factors in public health : The case of coronary heart disease
- 2017
-
Ingår i: SSM - Population Health. - : Elsevier BV. - 2352-8273. ; 3, s. 684-698
-
Tidskriftsartikel (refereegranskat)abstract
- Modern medicine is overwhelmed by a plethora of both established risk factors and novel biomarkers for diseases. The majority of this information is expressed by probabilistic measures of association such as the odds ratio (OR) obtained by calculating differences in average "risk" between exposed and unexposed groups. However, recent research demonstrates that even ORs of considerable magnitude are insufficient for assessing the ability of risk factors or biomarkers to distinguish the individuals who will develop the disease from those who will not. In regards to coronary heart disease (CHD), we already know that novel biomarkers add very little to the discriminatory accuracy (DA) of traditional risk factors. However, the value added by traditional risk factors alongside simple demographic variables such as age and sex has been the subject of less discussion. Moreover, in public health, we use the OR to calculate the population attributable fraction (PAF), although this measure fails to consider the DA of the risk factor it represents. Therefore, focusing on CHD and applying measures of DA, we re-examine the role of individual demographic characteristics, risk factors, novel biomarkers and PAFs in public health and epidemiology. In so doing, we also raise a more general criticism of the traditional risk factors' epidemiology. We investigated a cohort of 6103 men and women who participated in the baseline (1991-1996) of the Malmö Diet and Cancer study and were followed for 18 years. We found that neither traditional risk factors nor biomarkers substantially improved the DA obtained by models considering only age and sex. We concluded that the PAF measure provided insufficient information for the planning of preventive strategies in the population. We need a better understanding of the individual heterogeneity around the averages and, thereby, a fundamental change in the way we interpret risk factors in public health and epidemiology.
|
|
| 25. |
- Mulinari, Shai, et al.
(författare)
-
Advancing international comparison of pharmaceutical industry funding of patient advocacy: Focus on Denmark
- 2022
-
Ingår i: Health Policy. - : Elsevier BV. - 1872-6054 .- 0168-8510. ; 126:12, s. 1256-1262
-
Tidskriftsartikel (refereegranskat)abstract
- Pharmaceutical industry funding of patient organizations raises ethical challenges related to patient engagement in healthcare due to fears of commercial agendas influencing patient advocacy and creating industry-driven inequalities across patient organizations. We contribute to an international body of knowledge on patient organization–industry relations by analyzing all payments reported by companies in Denmark over a six-year period, 2014–2019. We performed descriptive analyses calculating the number, value, and distribution of payments for various units of analysis: all companies and patient organizations; individual companies and patient organizations; and the broader disease area (e.g., cancer) and narrower disease (e.g., breast cancer). Fifty-one companies reported paying €8,826,916 to 84 patient organizations. As in previously studied countries, the funding was dominated by a relatively small number of funders and recipients, and commercially high-profile diseases attracted most of the funding. Nevertheless, our study also highlighted the arguably concerning dominance of one company in Denmark, both at the level of overall funding and in funding specific patient organizations, during a time of great policy contention surrounding one of its drugs, the world’s top-selling medicine; i.e., switching patients to cheaper biosimilars to save big money for the healthcare system. Patient organizations have reasons to rethink some collaborations with companies, especially during policy contentions, and governments should ensure equitable funding to counteract risks posed by the concentration of industry funding.
|
|
